Hyderabad, India
Hyderabad, India

Time filter

Source Type

Patent
Dr. Reddys Laboratories Ltd. | Date: 2017-03-15

The application provides formulations for the topical administration of an active agent comprising at least one steroid, in the form of topical sprays that are propellant-free, and/or substantially non-foaming, and/or alcohol-free. The present application also provides processes for preparing such compositions and methods of using them in management of skin diseases or disorders such as psoriasis, dermatoses, and other associated skin diseases or disorders.


Patent
Dr. Reddys Laboratories Ltd. | Date: 2016-10-28

The present application relates to a method of treating a migraine headache in a patient by administering a pharmaceutical composition including rizatriptan or pharmaceutically acceptable salts thereof contained in a unit dose.


Patent
Dr. Reddys Laboratories Ltd. | Date: 2016-12-09

The present invention relates to a stable oral liquid pharmaceutical composition of celecoxib or its pharmaceutically acceptable salts thereof. The celecoxib present in the compositions as described herein do not show any precipitation when subjected in Fasted-State Simulated Gastric Fluid (FaSSGF) at pH 2.0, temperature of 37 C.0.5 C. and under stirring at a speed of 50 rpm at least for 60 minutes. It also relates to the process of preparing and method of using said composition of celecoxib.


Patent
Dr. Reddys Laboratories Ltd. | Date: 2017-05-10

The present application relates to the solid state forms of Eliglustat hemitartrate and the processes for the preparation thereof. The application further provides solid dispersion of Eliglustat hemitartrate having Eliglustat hemitartrate in amorphous form.


Patent
Dr. Reddys Laboratories Ltd. | Date: 2017-05-10

Aspects of the present invention provide stable liquid ready-to-use injectable formulation of bortezomib or pharmaceutically acceptable salts thereof. Another aspect of the present invention provides processes for preparation of such stable liquid ready- to-use injectable formulation of bortezomib and methods of using such formulations for treating various types of cancers in mammals.


Patent
DR. REDDYS LABORATORIES Ltd | Date: 2017-01-10

The present invention relates to stable liquid pharmaceutical formulations of cyclophosphamide comprising cyclophosphamide and at least one pharmaceutically acceptable excipient wherein moisture content of the liquid formulation is less than about 2.0% by weight. The invention further relates to stable liquid formulations of cyclophosphamide prepared by a process comprising a step of reducing the moisture content from cyclophosphamide or liquid compositions of cyclophosphamide or both. The invention further relate to method of using such stable liquid formulations of cyclophosphamide for parenteral administration either as ready-to-use or ready-to-dilute for treating various cancer disorders.


Patent
Dr. Reddys Laboratories Ltd., Sasmal, Ahmed, Tehim and Paradkar | Date: 2017-04-26

The present application relates to a series of substituted imidazo[l,2-a]pyridine compounds of formula (I), pharmaceutically acceptable salts, pharmaceutically acceptable solvates or stereoisomers thereof, their use as tropomyosin receptor kinase (Trk) family protein kinase inhibitors, method of making and pharmaceutical compositions comprising such compounds.


The invention relates to a cell culture process for decreasing the galactosylated content and/or increasing the G0F content of a glycoprotein. The process involves subjecting recombinant cells expressing the said glycoprotein to a temperature and pH shift and supplementing cell culture with glutamine.


Patent
DR. REDDYS LABORATORIES Ltd | Date: 2017-02-16

The invention provides a pharmaceutical composition for intranasal administration comprising a salt of sumatriptan or a physiologically acceptable solvate thereof, an alkyl glycoside or saccharide alkyl ester and optionally at least one pharmaceutically acceptable excipient, wherein the said composition provides T_(max )value of less than 30 minutes upon said administration. Other aspects and embodiments are contemplated and described. The invention also provides a pharmaceutical composition for intranasal administration comprising a triptan, a pharmaceutically acceptable vehicle and a mucosal permeation enhancer, wherein upon said administration said composition provides a T_(max )substantially equivalent to subcutaneous administration of said triptan. Other aspects and embodiments are contemplated and described.


Patent
Dr. Reddys Laboratories Ltd. | Date: 2017-06-14

A process for preparing Nilotinib hydrochloride Form R5 and Form R6 comprises: step a) providing a solution of Nilotinib free base in acetic acid and optionally an organic solvent, step b) adding hydrochloric acid taken in an organic solvent to the solution of step a), then separating Nilotinib hydrochloride Form R5 (step c), and finally drying at about 100 C to 150 C to obtain Nilotinib hydrochloride Form R6.

Loading Dr. Reddys Laboratories Ltd collaborators
Loading Dr. Reddys Laboratories Ltd collaborators